Document is current
Any future updates will be listed below
-
Authors
Jain, Anish J.
Lendoire, Mateo
Haddad, Antony
Tzeng, Ching-Wei D.
Boyev, Artem
Maki, Harufumi
Chun, Yun Shin
Arvide, Elsa M.
Lee, Sunyoung
Hu, Ian
Pant, Shubham
Javle, Milind
Tran Cao, Hop S.
Vauthey, Jean-Nicolas
Newhook, Timothy E.
- License Information
-
More Information
Article History
First Online: 25 March 2025
Disclosure
: Shubham Pant reports consulting or advisory role at Zymeworks, Ipsen, Novartis, Janssen, AskGene Pharma, BPGBio, Jazz Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, USWorldmeds, Nihon Medi-Physics Co, Ltd, Alligator Bioscience, Revolution Medicine, Theriva Biosciences, Arcus, BMS, Merck, and Pfizer; research funding (funding to institution) from Mirati Therapeutics, Lilly, Novartis, Bristol-Myers Squibb, Astellas, Framewave, Boehringer Ingelheim, NGM Pharmaceuticals, Janssen, Arcus, Elicio, Biontech, Ipsen, Zymeworks, Pfizer, ImmunoMET, Immuneering, Amal Therapeutics, Jazz Therapeutics, and Revolution medicine; and stock in Telperian.
